• Vaccine Name: live attenuated Brucella canis virB11 deletion mutant vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009264
• Type: Live attenuated vaccine
• Status: Research
• Host Species for Licensed Use: Dog
• Host Species as Laboratory Animal Model: Mus musculus
• Antigen: virB11 deletion mutant
• Preparation: Live attenuated Brucella canis virB11 deletion mutant strain. (Palomares-Resendiz et al, 2012)
• Description: A virB11 deletion mutant was constructed in Brucella canis to reduce virulence. Efficacy: The virB11 mutant was cleared by day 21 post-infection; no significant reduction in CFU after challenge reported. Immune response: Similar antibody isotype levels (IgG1, IgG2a, IgG2b, IgM) compared to wild-type; mild and constant IFN-γ response over time, unlike the rapid strong IFN-γ response induced by wild-type strain. (Palomares-Resendiz et al, 2012)

Mouse Response

• Immune Response: Similar antibody isotype levels (IgG1, IgG2a, IgG2b, IgM) compared to wild-type; mild and constant IFN-γ response over time, unlike the rapid strong IFN-γ response induced by wild-type strain. (Palomares-Resendiz et al, 2012)
• Challenge Protocol: Mouse model infection and challenge with wild-type B. canis; measurement of bacterial clearance, antibody isotypes, and cytokine production in lymphocyte cultures. (Palomares-Resendiz et al, 2012)
• Efficacy: The virB11 mutant was cleared by day 21 post-infection; no significant reduction in CFU after challenge reported. (Palomares-Resendiz et al, 2012)
• Description: Mouse model infection and challenge with wild-type B. canis; measurement of bacterial clearance, antibody isotypes, and cytokine production in lymphocyte cultures. (Palomares-Resendiz et al, 2012)